Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse-Reference-Cited by-同舟云学术

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

Published:2016-04-06 Issue:333 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Pu Yang¹²,Xu Meng³,Liang Yong⁴,Yang Kaiting⁴,Guo Yajun¹,Yang Xuanming⁵,Fu Yang-Xin²³⁴

Affiliation:

1. School of Bioscience and Bioengineering, South China University of Technology (SCUT), Guangzhou 510006, China.

2. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.

3. Department of Pathology, University of Chicago, Chicago, IL 60637, USA.

4. IBP-UTSW Joint Immunotherapy Group, Chinese Academy of Science Key Laboratory for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.

5. School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.

Abstract

Chemical androgen deprivation therapy may suppress adaptive immune responses and block the efficacy of immunotherapy.

Funder

NIH

National 12.5 Major Project of China

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference46 articles.

1. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

2. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

3. Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

4. Coercion, Incarceration, and Chemical Castration: An Argument From Autonomy

5. Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy;Journal for ImmunoTherapy of Cancer;2024-07

2. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future;Frontiers in Pharmacology;2024-05-30

3. Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor;Frontiers in Immunology;2024-05-28

4. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer;Clinical Cancer Research;2024-04-29

5. Inhibition of inosine metabolism of the gut microbiota decreases testosterone secretion in the testis;mSystems;2024-04-16